Delivery Order SPE2DB22D1106-SPE2DB25FFBM9
- Not listed
- The Defense Logistics Agency awarded a $31,152.11 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes with a completion date of August 5, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $10,777.92 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL syringes on July 18, 2025, with completion scheduled for July 21, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $1,709.46 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes. The contract, which is a non-set-aside competitive award with firm fixed pricing, is scheduled for completion by August 12, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $17,017.67 to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's headquarters location...
- The Defense Logistics Agency awarded a $14,845.54 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on July 23, 2025, with completion scheduled for July 24, 2025. This competitively awarded, firm fixed price contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication primarily used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a $4,171.54 delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of August 4, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order valued at $1,709.46 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes on August 4, 2025, with completion scheduled for August 5, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,709.46 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes on July 26, 2025, with an ultimate completion date of July 28, 2025. This firm fixed price contract represents a non-competitive set-aside order placed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999. The order will be fulfilled from...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for Dupixent 300mg/2ml syringes valued at $44,390.30. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 20, 2025, with performance at the contractor's corporate office location in Conshohocken, Pennsylvania. The award does not utilize a set-aside designation and represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $18,005.78 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFBM9Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $17,094.60 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 ml syringes on August 4, 2025, with an ultimate completion date of August 5, 2025. The contract utilizes firm fixed pricing and carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters. This delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen Drug Corp serves as a critical federal medical procurement vendor for military and veteran healthcare systems. Dupixent (dupilumab) is a biologic medication used primarily to treat moderate-to-severe atopic dermatitis, moderate-to-severe asthma, and chronic rhinosinusitis with nasal polyps. The delivery order reflects AmerisourceBergen's established capability to fulfill specialized pharmaceutical requirements across multiple therapeutic domains through the DLA's Pharmaceutical Prime Vendor program, which supports Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.1k | 8/4/25 |